IGF-1LR3 (0.1mg / 1mg) appears in Growth Research catalogs for qualified buyers who need specification, COA, and RUO clarity—IGF-1LR3 Specification and Vial Format Review summarizes key checks.
IGF-1LR3 is a long-arginine analog of insulin-like growth factor 1 used in laboratory research on IGF-1 receptor signaling, protein analog behavior, cell-growth pathway models, and peptide structure-activity studies.
IGF-1 LR3 contains an arginine substitution at position 3 and a 13-amino-acid extension reducing IGF-binding protein affinity, prolonging receptor engagement in cell culture. Research examines PI3K–Akt and MAPK pathway phosphorylation time courses in myoblast and fibroblast lines treated with LR3 versus native IGF-1.
Receptor autophosphorylation assays, cell proliferation curves, and apoptosis markers (cleaved caspase-3) are common endpoints. Muscle cell differentiation studies cite LR3 analogs when IGFBP interference must be minimized in serum-free experimental systems.
Principal investigators should sign off IGF-1LR3 SKUs only after mechanism fit is documented in the study protocol. Spec alignment: Enter exact strength notation (0.1mg / 1mg) in procurement systems—do not round kit counts.
Side-by-side review of specification table, vial label, and COA prevents release errors for IGF-1LR3.
Catalog identifiers for IGF-1LR3: CAS 946870-92-4, Formula: C400H625N111O115S9. MW Approx. 9.1 kDa, purity target ≥ 99.0%. Copy these fields into requisitions and match them line-by-line on incoming COA PDFs.
Publication methods should list Cat No. and mg strength for IGF-1LR3 to support reproducibility.
Dose planning for IGF-1LR3 should state mass (0.1mg / 1mg) or molarity derived from catalog molecular weight.
Specification alignment for IGF-1LR3 requires copying exact kit notation (0.1mg / 1mg) into ERP or LIMS systems. Rounding “10mg×10 vials” to “100mg total” causes mismatches when COA lists per-vial strength and suppliers ship multi-vial kits. Molecular identifiers for IGF-1LR3—CAS 946870-92-4, molecular weight, and formula when listed—should appear on internal sample labels alongside Cat No. Publications citing IGF-1LR3 should include these fields for reproducibility in Growth Research journals.
Format selection for IGF-1LR3 affects reconstitution math and aliquot planning. Compare available vial strengths on sulanpeptide.vip against protocol dose ranges before leadership approves a SKU; changing strength mid-study complicates comparability. Side-by-side review of catalog specification table, quote confirmation, vial label, and COA prevents release errors for IGF-1LR3. QA sign-off should reference all four documents in the batch record.
Purity target ≥ 99.0% on the catalog is a specification goal. Release criteria for IGF-1LR3 should state whether the lot COA must meet or exceed that threshold for your Growth Research assay type.
Side-by-side review of catalog specification table, quote confirmation, vial label, and COA prevents release errors for IGF-1LR3. QA sign-off should reference all four documents in the batch record. Purity target ≥ 99.0% on the catalog is a specification goal. Release criteria for IGF-1LR3 should state whether the lot COA must meet or exceed that threshold for your Growth Research assay type.
Format selection for IGF-1LR3 affects reconstitution math and aliquot planning. Compare available vial strengths on sulanpeptide.vip against protocol dose ranges before leadership approves a SKU; changing strength mid-study complicates comparability.
IGF-1LR3 from Sulan Peptide Official is for research use only (RUO)—not for human or veterinary use. Questions: Contact page or WhatsApp on sulanpeptide.vip.